Capecitabine in Low Risk Triple Negative Breast Cancer
Status:
NOT_YET_RECRUITING
Trial end date:
2030-01-31
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the efficacy and safety of capecitabine as the only adjuvant chemotherapy drug in patients with low-risk early triple-negative breast cancer who have received adequate local treatment. Patients meeting the inclusion criteria will receive capecitabine metronomic therapy for one year.